Therapeutic Solutions International Announces Clinical Proof of Concept of Nanoparticle Pterostilbene Formulation: NanoStilbene™

Early Clinical Trial Data Supports Enhanced Biodistribution of NanoStilbene™ Compared to Standard Pterostilbene
When Orally Administered

OCEANSIDE, Calif., July 02, 2018 (GLOBE NEWSWIRE) — Via OTC PR Wire — Therapeutics Solutions International, Inc., (OTC Markets:TSOI) announced today pilot clinical data providing proof of concept that its NanoStilbene™ formulation of pterostilbene more effectively increases blood levels of the molecule as compared to conventional formulations. The clinical trial involves administration of NanoStilbene or comparator formulations of pterostilbene, to healthy volunteers, followed by a series of blood draws to determine the concentration of the compound.

“These early studies are critical to establishing the efficacy of our nanoparticle formulations to effectively deliver pterostilbene to the body,” said Timothy Dixon, President, and CEO of Therapeutic Solutions International. “We are dedicated to developing First Class nutraceutical formulations that are science-driven. Through performing scientific validation at each step of the development process, we aim to fulfill this commitment to the Industry.”

Pterostilbene is a naturally occurring analog of resveratrol, which has been published in the peer-reviewed literature to suppress the growth of various types of cancers1 including cervical cancer2, lung cancer3, triple negative breast cancer4, prostate cancer5, and glioma6.

“I am extremely pleased with the promising initial data we are receiving demonstrating efficacy of the NanoStilbene formulation to deliver enhanced concentrations of pterostilbene to the patient’s blood stream,” said Dr. James Veltmeyer, Chief Medical Officer of the Company. “Given the ability of pterostilbene to enhance the efficacy of chemotherapeutic drugs7, as well as having activity as a monotherapy in animal models, we are hoping to expand the use of this highly interesting molecule.”

1 Chen et al. Apoptotic and Nonapoptotic Activities of Pterostilbene against Cancer. Int. J. Mol. Sci. 2018, 19(1), 287; http://www.mdpi.com/1422-0067/19/1/287

2Chatterjee et al. Resveratrol and Pterostilbene Exhibit Anticancer Properties Involving the Downregulation of HPV Oncoprotein E6 in Cervical Cancer Cells. Nutrients. 2018 Feb 21;10(2) http://www.mdpi.com/2072-6643/10/2/243

3 Ma et al. Pterostilbene exerts anticancer activity on non-small-cell lung cancer via activating endoplasmic reticulum stress. Sci Rep. 2017 Aug 14;7(1):8091. https://www.nature.com/articles/s41598-017-08547-0

4 Su et al. Pterostilbene inhibits triple-negative breast cancer metastasis via inducing microRNA-205 expression and negatively modulates epithelial-to-mesenchymal transition. J Nutr Biochem. 2015 Jun;26(6):675-85 https://www.ncbi.nlm.nih.gov/pubmed/25792283

5 Li et al. Pterostilbene acts through metastasis-associated protein 1 to inhibit tumor growth, progression and metastasis in prostate cancer. PLoS One. 2013;8(3):e57542. http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0057542

6 Huynh et al. Pterostilbene suppressed irradiation-resistant glioma stem cells by modulating GRP78/miR-205 axis. J Nutr Biochem. 2015 May;26(5):466-75. https://www.ncbi.nlm.nih.gov/pubmed/25736407

7 Schmidt et al. Case-specific potentiation of glioblastoma drugs by pterostilbene. Oncotarget. 2016 Nov 8;7(45):73200-73215. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5341973/

About Therapeutic Solutions International, Inc.

Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases. Immune modulation refers to the ability to upregulate (make more active) or downregulate (make less active) one’s immune system. The Company’s corporate website is www.therapeuticsolutionsint.com and e-commerce at www.youcanordernow.com.

Safe Harbor Statement
This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like “may,” “will,” “should,” “could,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” or “project” or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous risk factors as set forth in our SEC filings. To the extent that statements in this press release are not strictly historical, including statements as to product launch timing, revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future collaboration agreements, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made.

CONTACT INFORMATION